Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11678MR)

This product GTTS-WQ11678MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11678MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5867MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ2317MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ7707MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ9246MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ5103MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ15831MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3814MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ6716MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW